Risk for stroke, MI, all-cause mortality similar for those initiating SGLT-2i or metformin<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, May 24, 2022 (HealthDay News) — For patients with type 2 diabetes (T2D) receiving first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i), the risk for stroke, myocardial infarction (MI), and all-cause mortality is similar to those receiving metformin, and the risk for hospitalization for heart failure (HHF) is lower, according to a study published online May 24 in the Annals of Internal Medicine<\/em>.<\/p>\n HoJin Shin, Ph.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin during April 2013 to March 2020 using claims data from two large U.S. commercial and Medicare databases (8,613 and 17,226 patients, respectively).<\/p>\n The researchers found that during a mean follow-up of 12 months, SGLT-2i initiators had a similar risk for the composite of hospitalization for MI, hospitalization for ischemic or hemorrhagic stroke, or all-cause mortality (MI\/stroke\/mortality) and a lower risk for the composite of HHF or all cause-mortality (HHF\/mortality). Compared with metformin, initiators receiving SGLT-2i had a significantly lower risk for HHF, a numerically lower risk for MI, and a similar risk for stroke, mortality, and MI\/stroke\/HHF\/mortality. The risk for genital infections was increased for initiators receiving SGLT-2i; otherwise, safety was similar.<\/p>\n “Although our findings may support the use of SGLT-2i as first-line T2D treatment of cardiovascular outcomes, further research, that is, a randomized clinical trial, is warranted to establish more robust evidence,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n